Neuroscience & CNS
Part of Biotech - Drug Development
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 BIIB | Biogen Inc. Common Stock | $27.5b | $180.63 | -2.0% | 1.1M |
 NBIX | Neurocrine Biosciences Inc | $12.9b | $128.04 | +0.3% | 1.5M |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $11.5b | $29.23 | +6.3% | 161.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $11.3b | $201.26 | +2.4% | 1.3M |
 AXSM | Axsome Therapeutics, Inc | $8.2b | $187.26 | +0.7% | 919.9K |
 CYTK | Cytokinetics Inc. | $7.8b | $61.63 | -5.7% | 2.3M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $7.7b | $331.16 | -4.0% | 358.6K |
 PTCT | PTC Therapeutics, Inc. | $5.4b | $69.23 | +1.5% | 1.1M |
 XENE | Xenon Pharmaceuticals Inc | $5.3b | $54.22 | -1.9% | 693.9K |
 TGTX | TG Therapeutics, Inc. | $5.0b | $35.38 | -3.4% | 1.7M |
 ALKS | Alkermes Inc. plc | $5.0b | $33.73 | +1.3% | 1.7M |
 ACAD | Acadia Pharmaceuticals Inc. | $3.6b | $22.30 | +1.6% | 1.1M |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $3.5b | $34.30 | +3.2% | 2.8M |
 DNLI | Denali Therapeutics Inc. Common Stock | $2.9b | $19.96 | +0.5% | 1.0M |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.8b | $49.48 | -0.6% | 709.3K |
 ALMS | Alumis Inc. Common Stock | $2.6b | $24.77 | -0.7% | 1.1M |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.9b | $33.74 | -0.8% | 276.0K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $1.7b | $20.97 | -6.7% | 2.0M |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $1.6b | $31.05 | +0.8% | 831.9K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $1.4b | $16.86 | -1.1% | 859.2K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.3b | $35.40 | -3.2% | 246.8K |
 ATAI | AtaiBeckley Inc. Common Stock | $1.2b | $4.33 | -6.5% | 5.2M |
 BHVN | Biohaven Ltd. | $1.2b | $9.59 | -2.9% | 1.4M |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.2b | $6.46 | +0.9% | 2.0M |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.0b | $32.82 | +1.0% | 468.1K |
 GHRS | GH Research PLC Ordinary Shares | $0.8b | $19.56 | -3.4% | 256.2K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.8b | $30.71 | +3.2% | 494.1K |
 TBPH | Theravance Biopharma, Inc. | $0.8b | $16.82 | +2.2% | 255.6K |
 ANNX | Annexon, Inc. Common Stock | $0.7b | $6.13 | +4.2% | 3.1M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $90.10 | +1.1% | 217.9K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $7.03 | -2.6% | 1.4M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.7b | $31.87 | +3.7% | 242.3K |
 ANRO | Alto Neuroscience Inc. | $0.6b | $24.27 | -1.0% | 185.3K |
 PRTA | Prothena Corporation plc Ordinary Shares | $498.0m | $10.81 | +0.6% | 314.3K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $493.1m | $4.11 | +0.7% | 786.0K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $465.2m | $13.06 | +5.2% | 159.7K |
 VNDA | Vanda Pharmaceuticals Inc. | $393.1m | $6.80 | -1.3% | 1.4M |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $328.0m | $2.21 | -1.8% | 952.6K |
 OVID | Ovid Therapeutics Inc. Common Stock | $318.7m | $2.71 | +4.2% | 1.3M |
 NGEN | NervGen Pharma Corp. Common stock | $295.5m | $3.88 | -1.0% | 366.8K |
 PEPG | PepGen Inc. Common Stock | $292.4m | $1.60 | +3.9% | 1.2M |
 AVXL | Anavex Life Sciences | $261.3m | $3.31 | -0.9% | 739.8K |
 ACIU | AC Immune SA | $260.5m | $2.84 | 0.0% | 156.5K |
 NERV | Minerva Neurosciences, Inc | $258.3m | $6.42 | -2.4% | 168.5K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $230.6m | $3.77 | -0.5% | 369.5K |
 ALEC | Alector, Inc. Common Stock | $222.9m | $2.36 | -2.1% | 592.9K |
 HELP | Cybin Inc. Common Stock | $215.5m | $5.39 | -3.8% | 1.7M |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $208.6m | $1.89 | +0.5% | 690.5K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $205.6m | $3.46 | -0.1% | 1.6M |
 NTHI | NeOnc Technologies Holdings, Inc. Common Stock | $171.6m | $4.67 | -2.3% | 110.9K |